Richard Simoneaux writing for Oncology Times reported on a phase II study which includes patients with relapsed/refractory CLL who are ibrutinib-intolerant. The Context Simoneaux reports…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.